Stay up to date

The Global TB Vaccine R&D Roadmap was commissioned by the European & Developing Countries Clinical Trials Partnership (EDCTP) to the Amsterdam Institute for Global Health and Development (AIGHD) to identify priorities to coordinate global action to accelerate the development and implementation of new TB vaccines. The Roadmap has been developed through an iterative global consultative process designed to identify the key barriers to TB vaccine R&D and implementation, and potential ways in which they might be overcome. It is intended to provide a shared set of priorities to guide the activities of all stakeholders with an interest in TB vaccine development and use.AIGHD and EDCTP are pleased to invite the global TB vaccine community and interested stakeholders to attend the official launch of the Roadmap. The session opens with an introduction to the Roadmap, followed by an overview of current challenges and opportunities for TB vaccine R&D, and the perspective from a community representative. The presentations will be followed by a panel discussion with a diverse group of stakeholders, each sharing their comments on the Roadmap, their views on how they are planning to use it, and how they consider it can guide the future development of TB vaccines.

When: 20 April 2021, 18:00-19:30 CEST

Where: Virtual (Zoom)

REGISTER NOW: https://zoom.us/webinar/register/WN_pbpKgGpRR6ejZN1B-i0bxQ

Many national regulatory agencies in sub-Saharan Africa, which have responsibility for drug safety, lack the expertise, critical mass and infrastructure to monitor drug safety effectively during clinical trials and after licensing. The PhArmacoVIgilance Africa (PAVIA) project, implemented during the period 2018-2022 in Eswatini, Ethiopia, Nigeria and Tanzania, set out to strengthen pharmacovigilance in the African context. PAVIA incorporated the lessons and best practices from the project into a 'Blueprint for strengthening pharmacovigilance systems in resource-limited countries', and published the project’s outputs on The Global Health Network.

Read the blueprint https://media.tghn.org/medialibrary/2023/05/Pavia_Blueprint_FINAL.pdf

Project outputs on The Global Health Network: https://globalpharmacovigilance.tghn.org/pavia/

The HIV & Adolescence workshop is a highlight in my calendar every year. Unique because of its wholesale involvement of young people, state of the art keynote lectures, and engaging conversations involving young and older, clinician and non-clinicians, scientists, and advocates. It provides cutting-edge reviews of the latest innovation, science, and issues challenging young people in a world that is facing its 4th decade of battling HIV. If you need a dose of information, activism, hope, and education all in one workshop please join!

The International Workshop on HIV & Adolescence strongly believes in the engagement and inclusion of young people in the workshop.
We are pleased to waive the registration fee for all delegates that are 25 years of age and below.
Additionally, we offer a 50% discount on the registration fee for all delegates that are 30 years of age and below.
If you are eligible for this discount, please click the button below to submit your application.

For more information visit https://virology.eventsair.com/international-workshop-on-hiv-adolescence-2021/registration/Site/Register

Professor Collen Maisimirembwa, President and Chief Scientific Officer of the African Institute of Biomedical Sciences and Technology (AiBST), Zimbabwe was honoured by HUGO International for his contribution to genetics research in Africa. HUGO is a highly pretigious organization that championed the sequencing of the human genome. Professor Masimirembewa is a current EDCTP Senior Fellow (TMA2016SF1508) working on a project titled 'Pharmacogenomics research and clinical execellence in the treatment of infectious diseses in African populations (PRACE)'.

https://hugo-hgm.org/program/scientific#HUGOAfricanPrize